NASDAQ:HBIO - Harvard Bioscience Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.88 +0.18 (+4.86 %) (As of 03/21/2019 03:56 PM ET)Previous Close$3.70Today's Range$3.80 - $3.9552-Week Range$2.75 - $6.70Volume10,756 shsAverage Volume90,440 shsMarket Capitalization$146.16 millionP/E Ratio25.73Dividend YieldN/ABeta1.4 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts. Receive HBIO News and Ratings via Email Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorComputer and Technology Current SymbolNASDAQ:HBIO Previous Symbol CUSIP41690610 CIK1123494 Webwww.harvardbioscience.com Phone508-893-8999Debt Debt-to-Equity Ratio0.71 Current Ratio2.69 Quick Ratio1.49Price-To-Earnings Trailing P/E Ratio25.73 Forward P/E Ratio27.71 P/E GrowthN/A Sales & Book Value Annual Sales$120.77 million Price / Sales1.21 Cash Flow$0.3984 per share Price / Cash Flow9.74 Book Value$2.32 per share Price / Book1.67Profitability EPS (Most Recent Fiscal Year)$0.15 Net Income$-3,460,000.00 Net Margins-2.87% Return on Equity6.19% Return on Assets2.96%Miscellaneous EmployeesN/A Outstanding Shares37,670,000Market Cap$146.16 million Next Earnings Date5/1/2019 (Estimated) OptionableOptionable Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions What is Harvard Bioscience's stock symbol? Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO." How were Harvard Bioscience's earnings last quarter? Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its earnings results on Thursday, October, 25th. The medical instruments supplier reported $0.04 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.04. The medical instruments supplier had revenue of $28.71 million for the quarter, compared to analysts' expectations of $28.50 million. Harvard Bioscience had a negative net margin of 2.87% and a positive return on equity of 6.19%. View Harvard Bioscience's Earnings History. When is Harvard Bioscience's next earnings date? Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Harvard Bioscience. What guidance has Harvard Bioscience issued on next quarter's earnings? Harvard Bioscience issued an update on its FY 2019 earnings guidance on Thursday, February, 28th. The company provided earnings per share guidance of $0.21-0.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $124-126.5 million, compared to the consensus revenue estimate of $126.18 million. What price target have analysts set for HBIO? 2 equities research analysts have issued 1 year price targets for Harvard Bioscience's stock. Their predictions range from $11.00 to $11.00. On average, they expect Harvard Bioscience's share price to reach $11.00 in the next year. This suggests a possible upside of 183.5% from the stock's current price. View Analyst Price Targets for Harvard Bioscience. What is the consensus analysts' recommendation for Harvard Bioscience? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harvard Bioscience. Has Harvard Bioscience been receiving favorable news coverage? Media headlines about HBIO stock have trended somewhat positive on Thursday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Harvard Bioscience earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are some of Harvard Bioscience's key competitors? Some companies that are related to Harvard Bioscience include Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Arrayit (ARYC), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Precipio (PRPO) and PositiveID (PSID). What other stocks do shareholders of Harvard Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Micron Technology (MU), NVIDIA (NVDA), General Electric (GE), Johnson & Johnson (JNJ), AbbVie (ABBV), Celgene (CELG), Alibaba Group (BABA), Intel (INTC), Blackstone Group (BX) and Enterprise Products Partners (EPD). Who are Harvard Bioscience's key executives? Harvard Bioscience's management team includes the folowing people: Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 53)Ms. Kamalam Unninayar, Chief Financial OfficerMr. Russell J. Sylvia, VP of Global HRMr. Corey Manchester, VP & Corp. ControllerMr. Karl-Heinz Boven, VP & GM of Electrophysiology Who are Harvard Bioscience's major shareholders? Harvard Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.22%), Dimensional Fund Advisors LP (5.33%), Dimensional Fund Advisors LP (5.33%), Royce & Associates LP (4.64%), Acadian Asset Management LLC (2.17%) and Essex Investment Management Co. LLC (1.31%). Company insiders that own Harvard Bioscience stock include Earl R Lewis, George Uveges, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience. Which institutional investors are selling Harvard Bioscience stock? HBIO stock was sold by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC, Millennium Management LLC, Algert Global LLC, Two Sigma Investments LP, Acadian Asset Management LLC, Essex Investment Management Co. LLC, ClariVest Asset Management LLC and United Services Automobile Association. Company insiders that have sold Harvard Bioscience company stock in the last year include Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience. Which institutional investors are buying Harvard Bioscience stock? HBIO stock was bought by a variety of institutional investors in the last quarter, including Royce & Associates LP, Alambic Investment Management L.P., BlackRock Inc., Strs Ohio, Squarepoint Ops LLC, Geode Capital Management LLC, Geode Capital Management LLC and Rhumbline Advisers. Company insiders that have bought Harvard Bioscience stock in the last two years include Earl R Lewis, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience. How do I buy shares of Harvard Bioscience? Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Harvard Bioscience's stock price today? One share of HBIO stock can currently be purchased for approximately $3.88. How big of a company is Harvard Bioscience? Harvard Bioscience has a market capitalization of $146.16 million and generates $120.77 million in revenue each year. The medical instruments supplier earns $-3,460,000.00 in net income (profit) each year or $0.15 on an earnings per share basis. What is Harvard Bioscience's official website? The official website for Harvard Bioscience is http://www.harvardbioscience.com. How can I contact Harvard Bioscience? Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected] MarketBeat Community Rating for Harvard Bioscience (NASDAQ HBIO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 210 (Vote Outperform)Underperform Votes: 173 (Vote Underperform)Total Votes: 383MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe HBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: How Does the Quiet Period Work?